Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Patient Guide

Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a condition where the liver becomes a mirror for your body’s overall metabolic health. It begins when the liver accumulates excess fat, but unlike simple fat buildup, MASH involves active inflammation and injury to liver cells ^[1]. Over time, this chronic “fire” in the liver can lead to the formation of scar tissue, known as fibrosis, which is the most critical factor in determining your long-term health ^[2]. While the condition was previously known as NASH, the medical community updated the name to MASH to more accurately reflect that the disease is driven by metabolic factors like insulin resistance, obesity, and high blood pressure ^[3]. It is important to know that MASH activity and fibrosis (scarring) are separate dimensions—you can have active MASH with no scarring, or you could have significant scarring.

Understanding your diagnosis means looking at the liver not as an isolated organ, but as part of a complex metabolic system. While it is natural to focus on the liver itself, a major and often leading competing risk for people with MASH is actually cardiovascular disease, such as heart attack or stroke ^[4]. This connection exists because the same metabolic imbalances that damage the liver also affect the heart and blood vessels ^[5]. Therefore, effective management is “whole-body” care, focusing on blood sugar control, heart health, and weight management alongside liver-specific monitoring ^[6].

The journey with MASH is one of proactive management and, increasingly, hope. The liver is a remarkably resilient organ, and advanced stages of inflammation and early scarring can sometimes be halted or improved, though fibrosis regression is possible but not guaranteed, and established cirrhosis may persist even when the cause is treated ^[7]. Achieving a sustained weight loss of 7% to 10% remains a foundational goal, as it has been shown to significantly reduce liver fat and inflammation ^[8]. These lifestyle efforts are now being joined by new, targeted medications like resmetirom, the first FDA-approved treatment indicated specifically for adults with noncirrhotic MASH with moderate-to-advanced liver scarring (stages F2 to F3) ^[9]. By working with a multidisciplinary care team, you can take control of your metabolic health and give your liver the best environment possible to heal and thrive ^[1].

(Disclaimer: This guide is for informational purposes. Treatment, alcohol cessation, and medication decisions should be individualized with a clinician. Last medically reviewed: 2026-10-11)